Anlon's Rajkot capex balloons to ₹130 cr; ₹28 cr distributor default disclosed
The contract drugmaker quadrupled its planned spending on a new facility, taking on ₹65-70 crore in debt, and revealed a large receivables default only when pressed in the Q&A.
What's new
- Anlon quadrupled its planned capex for a new Rajkot facility to ₹130 crore, taking on ₹65-70 crore in bank debt to help fund it.
- A distributor default of ₹28 crore was disclosed, with ₹17 crore still outstanding.
- Revenue guidance for FY27 is ₹380-400 crore and for FY28 is ₹700-800 crore, backed by a ₹280-300 crore order book.
Why this matters
The scale-up in spending, financed by new debt, dramatically changes the financial profile of a micro-cap firm. Revealing a large receivables default only in the Q&A raises governance questions, while guidance implying over 120% revenue growth now hinges on flawless execution and collections.
What we're watching
- How the new bank term loan impacts interest costs and near-term cash flow.
- Progress on recovering the ₹17 crore still outstanding from the defaulted distributor.
- Execution of the CDMO pipeline after acknowledged delays in commercializing high-value molecules.
The full read
Anlon Healthcare's expansion story just got more expensive and riskier. The planned capex for its new Rajkot facility has exploded from ₹31 crore to ₹130 crore, with ₹65-70 crore coming from a new bank term loan. This introduces debt to the balance sheet of a micro-cap firm that previously funded growth internally. The company also disclosed a ₹28 crore distributor default, with ₹17 crore still uncollected, a fact revealed only during the Q&A. Guidance for FY27 revenue of ₹380-400 crore implies a massive growth target, but that target now carries two new material risks: higher debt and a large receivable that has already soured. Management acknowledged delays in commercializing its high-value CDMO molecules, adding execution questions to the funding ones. The order book of ₹280-300 crore provides a base, but the path to FY28 revenue of ₹700-800 crore runs through a facility that costs four times as much and a collector's office that just lost ₹17 crore.
Questions answered
- How did the planned spending on the Rajkot facility change?
- Management more than quadrupled the capex estimate from ₹31 crore to ₹130 crore. It plans to fund the increase partly through a ₹65-70 crore bank term loan, introducing debt to the expansion.
- What is the status of the distributor default?
- Anlon disclosed a default worth ₹28 crore, of which ₹17 crore is still outstanding. This information came up during the Q&A portion of the call, not in the prepared remarks.
- What do the revenue guidance numbers imply?
- FY27 guidance of ₹380-400 crore implies a sharp revenue jump. The ₹280-300 crore order book underpins this target, but the company has acknowledged delays in its high-value CDMO pipeline.
- Why is the capex funding method significant?
- The company is taking on ₹65-70 crore in bank debt for a facility whose cost has quadrupled. This adds financial pressure at a time when a key receivable has gone bad, tightening cash flow.